AlzeCure Pharma has released new preclinical findings for its lead Alzheimer’s drug candidate, NeuroRestore ACD856, following a presentation at the AD/PD 2026 international conference.
The full presentation is now available on the company’s website and highlights emerging evidence supporting the compound’s mechanism of action and therapeutic potential.
Cristina Parrado-Fernández, senior scientist at AlzeCure, said: ‘These new data with ACD856 show that the compound has a clear biological effect on NGF and BDNF signaling mediated by TRK receptors. These systems play an important role in the normal function of neurons in the brain, and improved signaling leads to positive effects in disturbed systems, such as improved memory function and antidepressant effects.’
Her abstract, Characterization of mechanisms of action of NeuroRestore ACD856, a positive allosteric modulator of Trk-receptors under clinical development for Alzheimer’s disease, detailed new preclinical results examining how ACD856 exerts its biological effects.
According to the company, the studies demonstrated that the compound triggers dose-dependent activation of Trk receptors and downstream proteins, consistent with its intended mechanism.
These effects were also confirmed in vivo, where researchers observed a strong antidepressant response aligned with earlier findings. The company notes that this is particularly relevant given the high prevalence of depression among people with Alzheimer’s disease and the global burden of depressive disorders.
AlzeCure’s NeuroRestore platform aims to strengthen communication between nerve cells and improve cognitive functions such as learning and memory. Previous studies have also indicated neuroprotective and anti-inflammatory properties in models using these Trk-PAM substances.
ACD856, described as a first-in-class candidate, is being prepared for upcoming phase 2 clinical trials and recently received significant EU funding through the European Innovation Council.
Martin Jönsson, CEO of AlzeCure, explained: ‘With the positive clinical results that we previously obtained with ACD856, as well as the new preclinical results that further support the target mechanism and show potent antidepressant effects, we have a very promising drug candidate in our research portfolio, which gives us increased opportunities, including in terms of business development, both for Alzheimer’s and depression.’
